The role of mitogen-activated protein kinase-activated protein kinase 2 in the p38/TNF-α pathway of systemic and cutaneous inflammation

Journal of Investigative Dermatology

Volumn 130, Issue 2, 2010, Pages 481-491

  Schottelius, Arndt J ^a   Zügel, Ulrich ^b   Döcke, Wolf Dietrich ^b   Zollner, Thomas M ^b   Röse, Lars ^b   Mengel, Anne ^b   Buchmann, Bernd ^b   Becker, Andreas ^b   Grütz, Gerald ^c   Naundorf, Sandra ^c   Friedrich, Anke ^c   Gaestel, Matthias ^d   Asadullah, Khusru ^b  

^a MORPHOSYS AG   (Germany)

^b BAYER PHARMA AG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; 2 O TETRADECANOYLPHORBOL 13 ACETATE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ENDOTOXIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTACT ALLERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; FEMALE; GRANULOCYTE; IRRITANT DERMATITIS; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SKIN EDEMA; SKIN INFLAMMATION; T LYMPHOCYTE;

EID: 75549090082     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.218     Document Type: Article

References (33)

1. Alford JG, Stanley PL, Todderud G, Tramposch KM (1992) Temporal infiltration of leukocyte subsets into mouse skin inflamed with phorbol ester. Agents Actions 37:260-267
2. Allen M, Svensson L, Roach M, Hambor J, McNeish J, Gabel CA (2000) Deficiency of the stress kinase p38alpha results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J Exp Med 191:859-870
3. Anderson DR, Meyers MJ, Vernier WF, Mahoney MW, Kurumbail RG, Caspers N et al. (2007) Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem 50:2647-2654
4. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE (1996) Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 279:1453-1461
5. Dambach DM (2005) Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr Top Med Chem 5:929-939
6. Duraisamy S, Bajpai M, Bughani U, Dastidar SG, Ray A, Chopra P (2008) MK2: a novel molecular target for anti-inflammatory therapy. Expert Opin Ther Targets 12:921-936
7. Funding AT, Johansen C, Gaestel M, Bibby BM, Lilleholt LL, Kragballe K et al. (2009) Reduced oxazolone-induced skin inflammation in MAPKAP kinase 2 knockout mice. J Invest Dermatol 129:891-898
8. Gaestel M (2006) MAPKAP kinases-MKs-two's company, three's a crowd. Nat Rev Mol Cell Biol 7:120-130
9. Gaestel M, Mengel A, Bothe U, Asadullah K (2007) Protein kinases as small molecule inhibitor targets in inflammation. Curr Med Chem 14:2214-2234
10. Gaestel M, Kotlyarov A, Kracht M (2009) Targeting innate immunity protein kinase signaling in inflammtion. Nat Rev Drug Discov 8:480-499
11. Gorska MM, Liang Q, Stafford SJ, Goplen N, Dharajiya N, Guo L et al. (2007) MK2 controls the level of negative feedback in the NF-kappaB pathway and is essential for vascular permeability and airway inflammation. J Exp Med 204:1637-1652
12. Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ (2007) Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Natu Immunol 8:1095-1104
13. Hegen M, Gaestel M, Nickerson-Nutter CL, Lin LL, Telliez JB (2006) MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis. J Immunol 177:1913-1917
14. Jackson JR, Bolognese B, Hillegass L, Kassis S, Adams J, Griswold DE et al. (1998) Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 284:687-692
15. Johansen C, Funding AT, Otkjaer K, Kragballe K, Jensen UB, Madsen M et al. (2006) Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 176:1431-1438
16. Johansen C, Kragballe K, Westergaard M, Henningsen J, Kristiansen K, Iversen L (2005) The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 152:37-42
17. Kontoyiannis D, Boulougouris G, Manoloukos M, Armaka M, Apostoloki M, Pizarro T et al. (2002) Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's like inflammatory bowel disease. J Exp Med 196:1563-1574
18. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD et al. (1999) MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1:94-97
19. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D et al. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746
20. Lu HT, Yang DD, Wysk M, Gatti E, Mellman I, Davis RJ et al. (1999) Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J 18:1845-1857
21. Manome H, Aiba S, Tagami H (1999) Simple chemicals can induce maturation and apoptosis of dendritic cells. Immunology 98:481-490 (Pubitemid 30005327)
22. Neininger A, Kontoyiannis D, Kotlyarov A, Winzen R, Eckert R, Volk HD et al. (2002) MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J Biol Chem 277:3065-3068
23. O'Leary JG, Goodarzi M, Drayton DL, von Andrian UH (2006) T cell-and B cell-independent adaptive immunity mediated by natural killer cells. Nat Immunol 7:507-516
24. Rogers DF, Giembycz MA (1998) Asthma therapy for the 21st century. Trends Pharmacol Sci 19:160-164
25. Ronkina N, Kotlyarov A, Dittrich-Breiholz O, Kracht M, Hitti E, Milarski K et al. (2007) The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol Cell Biol 27:170-181
26. Salvador JM, Mittelstadt PR, Guszczynski T, Copeland TD, Yamaguchi H, Appella E et al. (2005) Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat Immunol 6:390-395
27. Schottelius AJ, Giesen C, Asadullah K, Fierro IM, Colgan SP, Bauman J et al. (2002) An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J Immunol 169:7063-7070
28. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK III (2004) Biology of tumor necrosis factor-alpha-implications for psoriasis. Exp Dermatol 13:193-222
29. Takanami-Ohnishi Y, Amano S, Kimura S, Asada S, Utani A, Maruyama M et al. (2002) Essential role of p38 mitogen-activated protein kinase in contact hypersensitivity. J Biol Chem 277:37896-37903
30. Wang X, Xu L, Wang H, Young PR, Gaestel M, Feuerstein GZ (2002) Mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 deficiency protects brain from ischemic injury in mice. J Biol Chem 277:43968-43972
31. Wysk M, Yang DD, Lu HT, Flavell RA, Davis RJ (1999) Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumor necrosis factor-induced cytokine expression. Proc Natl Acad Sci USA 96:3763-3768
32. Zollner T, Igney FH, Asadullah K (2004) Acute and chronic models of allergic contact dermatitis: advantages and limitations. In: Animal Models of T Cell-Mediated Skin Diseases. (Zollner T, Renz H, Asadullah K, eds). Springer Berlin, Heidelberg, New York, ISBN: 3-540-21067-9, 255-275
33. Zugel U, Steinmeyer A, Giesen C, Asadullah K (2002) A novel immunosup-pressive 1alpha,25-dihydroxyvitamin D3 analog with reduced hypercal-cemic activity. J Invest Dermatol 119:1434-1442